Skip to main content
Publications
Hoffman E, Mladsi DM , Cryer B, Hopkins W, Brater DC, Parikh R , Goyal R , Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data . Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B , Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab . Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).
Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E , Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. HIFMECH Study Group. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study . J Thromb Haemost. 2003;1(11):2322-9.
Helliwell PS, Doward L , Whalley D , Tennant A, McKenna S, Reynolds S, Kay L, Spoorenberg A, van der Heijde Leeds D. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS) . Poster presented at the 1999 ACR/ARHP Annual Scientific Meeting; November 14, 1999. Boston, MA. [abstract] Arthritis Rheumatol. 1999 Sep; 42(S9):s72.